NCT04696731
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04696731
Title Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)
Acronym TRAVERSE
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
UCLA Medical Center Los Angeles California 90095 United States Details
UCSF Medical Center San Francisco California 94143 United States Details
Yale School of Medicine New Haven Connecticut 06520 United States Details
Georgetown University Hospital Washington D.C. District of Columbia 20007 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field